Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

F. Morschhauser, P. Feugier, IW. Flinn, R. Gasiorowski, R. Greil, Á. Illés, NA. Johnson, JF. Larouche, PJ. Lugtenburg, C. Patti, GA. Salles, M. Trněný, S. de Vos, F. Mir, D. Samineni, SY. Kim, Y. Jiang, E. Punnoose, A. Sinha, E. Clark, N....

. 2021 ; 137 (5) : 600-609. [pub] 20210204

Language English Country United States

Document type Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21019279

Grant support
P30 CA008748 NCI NIH HHS - United States
P50 CA192937 NCI NIH HHS - United States

The phase 2 CAVALLI (NCT02055820) study assessed efficacy and safety of venetoclax, a selective B-cell lymphoma-2 (Bcl-2) inhibitor, with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line (1L) diffuse large B-cell lymphoma (DLBCL), including patients demonstrating Bcl-2 protein overexpression by immunohistochemistry (Bcl-2 IHC+). Eligible patients were ≥18 years of age and had previously untreated DLBCL, Eastern Cooperative Oncology Group performance status ≤2, and International Prognostic Index 2 to 5. Venetoclax 800 mg (days 4-10, cycle 1; days 1-10, cycles 2-8) was administered with rituximab (8 cycles) and cyclophosphamide, doxorubicin, vincristine, and prednisone (6-8 cycles) in 21-day cycles. Primary end points were safety, tolerability, and research_plete response (CR) at end of treatment (EOT). Secondary end points were progression-free survival (PFS) and overall survival. Comparative analyses used covariate-adjusted R-CHOP controls from the GOYA/BO21005 study, an appropriate contemporary benchmark for safety and efficacy. Safety and efficacy analyses included 206 patients. CR rate at EOT was 69% in the overall population and was maintained across Bcl-2 IHC+ subgroups. With a median follow-up of 32.2 months, trends were observed for improved investigator-assessed PFS for venetoclax plus R-CHOP in the overall population (hazard ratio [HR], 0.61; 95% confidence interval [CI], 0.43-0.87) and Bcl-2 IHC+ subgroups (HR, 0.55; 95% CI, 0.34-0.89) vs R-CHOP. Despite a higher incidence of grade 3/4 hematologic adverse events (86%), related mortality was not increased (2%). Chemotherapy dose intensity was similar in CAVALLI vs GOYA. The addition of venetoclax to R-CHOP in 1L DLBCL demonstrates increased, but manageable, myelosuppression and the potential of improved efficacy, particularly in high-risk Bcl-2 IHC+ patient subgroups.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019279
003      
CZ-PrNML
005      
20210830100846.0
007      
ta
008      
210728s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood.2020006578 $2 doi
035    __
$a (PubMed)33538797
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Morschhauser, Franck $u Université de Lille, Centre Hospitalier Universitaire (CHU) Lille, Groupe de Recherche sur les Formes Injectables et les Technologies Associées (ULR 7365-GRITA), Lille, France
245    12
$a A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma / $c F. Morschhauser, P. Feugier, IW. Flinn, R. Gasiorowski, R. Greil, Á. Illés, NA. Johnson, JF. Larouche, PJ. Lugtenburg, C. Patti, GA. Salles, M. Trněný, S. de Vos, F. Mir, D. Samineni, SY. Kim, Y. Jiang, E. Punnoose, A. Sinha, E. Clark, N. Spielewoy, K. Humphrey, A. Bazeos, AD. Zelenetz
520    9_
$a The phase 2 CAVALLI (NCT02055820) study assessed efficacy and safety of venetoclax, a selective B-cell lymphoma-2 (Bcl-2) inhibitor, with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line (1L) diffuse large B-cell lymphoma (DLBCL), including patients demonstrating Bcl-2 protein overexpression by immunohistochemistry (Bcl-2 IHC+). Eligible patients were ≥18 years of age and had previously untreated DLBCL, Eastern Cooperative Oncology Group performance status ≤2, and International Prognostic Index 2 to 5. Venetoclax 800 mg (days 4-10, cycle 1; days 1-10, cycles 2-8) was administered with rituximab (8 cycles) and cyclophosphamide, doxorubicin, vincristine, and prednisone (6-8 cycles) in 21-day cycles. Primary end points were safety, tolerability, and research_plete response (CR) at end of treatment (EOT). Secondary end points were progression-free survival (PFS) and overall survival. Comparative analyses used covariate-adjusted R-CHOP controls from the GOYA/BO21005 study, an appropriate contemporary benchmark for safety and efficacy. Safety and efficacy analyses included 206 patients. CR rate at EOT was 69% in the overall population and was maintained across Bcl-2 IHC+ subgroups. With a median follow-up of 32.2 months, trends were observed for improved investigator-assessed PFS for venetoclax plus R-CHOP in the overall population (hazard ratio [HR], 0.61; 95% confidence interval [CI], 0.43-0.87) and Bcl-2 IHC+ subgroups (HR, 0.55; 95% CI, 0.34-0.89) vs R-CHOP. Despite a higher incidence of grade 3/4 hematologic adverse events (86%), related mortality was not increased (2%). Chemotherapy dose intensity was similar in CAVALLI vs GOYA. The addition of venetoclax to R-CHOP in 1L DLBCL demonstrates increased, but manageable, myelosuppression and the potential of improved efficacy, particularly in high-risk Bcl-2 IHC+ patient subgroups.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a bicyklické sloučeniny heterocyklické $x aplikace a dávkování $x škodlivé účinky $7 D019086
650    _2
$a cyklofosfamid $x aplikace a dávkování $x škodlivé účinky $7 D003520
650    _2
$a doxorubicin $x aplikace a dávkování $x škodlivé účinky $7 D004317
650    _2
$a únava $x chemicky indukované $7 D005221
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a gastrointestinální nemoci $x chemicky indukované $7 D005767
650    _2
$a geny bcl-2 $7 D019254
650    _2
$a faktor stimulující kolonie granulocytů $x terapeutické užití $7 D016179
650    _2
$a krevní nemoci $x chemicky indukované $7 D006402
650    _2
$a lidé $7 D006801
650    _2
$a infekce $x etiologie $7 D007239
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a difúzní velkobuněčný B-lymfom $x farmakoterapie $x genetika $7 D016403
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádorové proteiny $x antagonisté a inhibitory $7 D009363
650    _2
$a prednison $x aplikace a dávkování $x škodlivé účinky $7 D011241
650    _2
$a protoonkogenní proteiny c-bcl-2 $x antagonisté a inhibitory $7 D019253
650    _2
$a rituximab $x aplikace a dávkování $x škodlivé účinky $7 D000069283
650    _2
$a sulfonamidy $x aplikace a dávkování $x škodlivé účinky $7 D013449
650    _2
$a vinkristin $x aplikace a dávkování $x škodlivé účinky $7 D014750
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky, fáze I $7 D017426
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Feugier, Pierre $u CHU de Nancy, Université de Lorraine, Vandoeuvre lès Nancy, France
700    1_
$a Flinn, Ian W $u Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN
700    1_
$a Gasiorowski, Robin $u Concord Hospital, University of Sydney, Sydney, NSW, Australia
700    1_
$a Greil, Richard $u Paracelcus Medical University Salzburg, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, Salzburg, Austria
700    1_
$a Illés, Árpád $u Department of Hematology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
700    1_
$a Johnson, Nathalie A $u Jewish General Hospital, Montreal, QC, Canada
700    1_
$a Larouche, Jean-François $u CHU de Québec, Hôpital de l'Enfant-Jésus, Quebec City, QC, Canada
700    1_
$a Lugtenburg, Pieternella J $u HOVON Lunenburg Lymphoma Phase I-II Consortium, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
700    1_
$a Patti, Caterina $u Azienda Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy
700    1_
$a Salles, Gilles A $u Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, University of Lyon, Pierre-Bénite, France
700    1_
$a Trněný, Marek $u First Department of Medicine, Charles University General Hospital, Prague, Czech Republic
700    1_
$a de Vos, Sven $u David Geffen School of Medicine, University of California (UCLA), Los Angeles, CA
700    1_
$a Mir, Farheen $u Royal Marsden Hospital, Sutton, Surrey, United Kingdom
700    1_
$a Samineni, Divya $u Genentech, Inc., South San Francisco, CA
700    1_
$a Kim, Su Y $u AbbVie, North Chicago, IL
700    1_
$a Jiang, Yanwen $u Genentech, Inc., South San Francisco, CA
700    1_
$a Punnoose, Elizabeth $u Genentech, Inc., South San Francisco, CA
700    1_
$a Sinha, Arijit $u Roche Products Limited, Welwyn Garden City, United Kingdom
700    1_
$a Clark, Emma $u Roche Products Limited, Welwyn Garden City, United Kingdom
700    1_
$a Spielewoy, Nathalie $u F. Hoffmann-La Roche Ltd., Basel, Switzerland; and
700    1_
$a Humphrey, Kathryn $u Roche Products Limited, Welwyn Garden City, United Kingdom
700    1_
$a Bazeos, Alexandra $u Roche Products Limited, Welwyn Garden City, United Kingdom
700    1_
$a Zelenetz, Andrew D $u Memorial Sloan Kettering Cancer Center, New York, NY
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 137, č. 5 (2021), s. 600-609
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33538797 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100846 $b ABA008
999    __
$a ok $b bmc $g 1690169 $s 1139725
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 137 $c 5 $d 600-609 $e 20210204 $i 1528-0020 $m Blood $n Blood $x MED00000807
GRA    __
$a P30 CA008748 $p NCI NIH HHS $2 United States
GRA    __
$a P50 CA192937 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20210728
Back

Find record

Citation metrics

Archiving options